CA3242833A1 - OPHTHALMIC PHARMACEUTICAL COMPOSITIONS AND THEIR USES - Google Patents

OPHTHALMIC PHARMACEUTICAL COMPOSITIONS AND THEIR USES

Info

Publication number
CA3242833A1
CA3242833A1 CA3242833A CA3242833A CA3242833A1 CA 3242833 A1 CA3242833 A1 CA 3242833A1 CA 3242833 A CA3242833 A CA 3242833A CA 3242833 A CA3242833 A CA 3242833A CA 3242833 A1 CA3242833 A1 CA 3242833A1
Authority
CA
Canada
Prior art keywords
pharmaceutical compositions
ophthalmic pharmaceutical
ophthalmic
compositions
pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3242833A
Other languages
English (en)
French (fr)
Inventor
Anjali Joshi
Original Assignee
Alcon Inc
Aerie Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Inc, Aerie Pharmaceuticals Inc filed Critical Alcon Inc
Publication of CA3242833A1 publication Critical patent/CA3242833A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA3242833A 2021-12-17 2022-12-16 OPHTHALMIC PHARMACEUTICAL COMPOSITIONS AND THEIR USES Pending CA3242833A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163290781P 2021-12-17 2021-12-17
US63/290,781 2021-12-17
PCT/US2022/081775 WO2023114986A1 (en) 2021-12-17 2022-12-16 Ophthalmic pharmaceutical compositions and uses thereof

Publications (1)

Publication Number Publication Date
CA3242833A1 true CA3242833A1 (en) 2023-06-22

Family

ID=85157426

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3242833A Pending CA3242833A1 (en) 2021-12-17 2022-12-16 OPHTHALMIC PHARMACEUTICAL COMPOSITIONS AND THEIR USES

Country Status (10)

Country Link
US (3) US11850221B2 (enExample)
EP (1) EP4447935A1 (enExample)
JP (1) JP2024544393A (enExample)
KR (1) KR20240121320A (enExample)
CN (1) CN118076340A (enExample)
AU (2) AU2022409839B2 (enExample)
CA (1) CA3242833A1 (enExample)
IL (1) IL313616A (enExample)
MX (1) MX2024007092A (enExample)
WO (1) WO2023114986A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3242833A1 (en) 2021-12-17 2023-06-22 Alcon Inc. OPHTHALMIC PHARMACEUTICAL COMPOSITIONS AND THEIR USES
US20250384550A1 (en) * 2023-06-09 2025-12-18 Chung Shan Medical University Reagent and kit for identifying and diagnosis ocular surface disease (osd) and use thereof
US20260027050A1 (en) * 2024-07-23 2026-01-29 Alcon Inc. Acoltremon combinations and uses thereof
WO2026154426A1 (en) * 2025-01-16 2026-07-23 Alcon Inc. Ophthalmic pharmaceutical compositions and uses thereof

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH1067684A (ja) 1996-06-17 1998-03-10 Mitsubishi Chem Corp 涙液分泌促進剤
JPH10236972A (ja) 1997-02-28 1998-09-08 Mitsubishi Chem Corp 涙液分泌促進剤
JP3142842B1 (ja) 1999-10-22 2001-03-07 ライオン株式会社 眼科用組成物及びソフトコンタクトレンズへの吸着抑制方法
US6569903B2 (en) 1999-12-07 2003-05-27 Rohto Pharmaceutical Co., Ltd. Ophthalmic compositions
US20020009507A1 (en) 2000-01-19 2002-01-24 Alcon Universal Ltd. Use of polyethoxylated castor oil for the treatment of dry eye
AU2003210663A1 (en) 2002-01-25 2003-09-02 The Regents Of The University Of California Methods of modulating cold sensory perception
US20060084684A1 (en) 2002-05-28 2006-04-20 Altana Pharma Ag Topically applicable pharmaceutical preparation
US6919348B2 (en) 2002-05-02 2005-07-19 Edward T. Wei Therapeutic 1,2,3,6-tetrahydropyrimidine-2-one compositions and methods therewith
IL152486A0 (en) 2002-10-25 2003-05-29 Meir Eini Alcohol-free cosmetic and pharmaceutical foam carrier
DE10259619A1 (de) 2002-12-18 2004-07-08 Metagen Pharmaceuticals Gmbh Verwendung einer TRPM8 aktivierenden Substanz zur Tumorbehandlung
CA2530884C (en) 2003-07-02 2016-01-12 Genentech, Inc. Trp-p8 active compounds and therapeutic treatment methods
US20050137166A1 (en) 2003-12-19 2005-06-23 Alcon, Inc. Use of cooling agents to relieve mild ocular irritation and enhance comfort
EP1802600A1 (en) 2004-10-13 2007-07-04 Bayer HealthCare AG Substituted 4-benzyloxy-phenylmethylamide derivatives as cold menthol receptor-1 (cmr-1) antagonits for the treatment of urological disorders
US20060111388A1 (en) 2004-11-19 2006-05-25 University Of North Texas Health Science Center At Fort Worth Phenanthroline and derivatives thereof used to lower intraocular pressure in an affected eye
JP5078254B2 (ja) 2004-12-17 2012-11-21 ロート製薬株式会社 眼科用組成物
GB0504194D0 (en) 2005-03-02 2005-04-06 Givaudan Sa Organic compounds
WO2007017092A1 (en) 2005-08-04 2007-02-15 Bayer Healthcare Ag Substituted 4-benzyloxy-benzoic acid amide derivatives
US7727516B2 (en) 2006-02-28 2010-06-01 The Procter & Gamble Company Reduction of hair growth
CN101405009B (zh) 2006-03-23 2011-04-13 千寿制药株式会社 包含黄原胶和葡萄糖的眼科组合物
US7887859B2 (en) 2006-11-02 2011-02-15 Riolan Technologies, Inc. Methods of treating epiphora
GB2451503B (en) 2007-08-01 2011-10-12 Lrc Products Stimulating gel comprising a cyclic carboxamide coolant
FR2934778B1 (fr) 2008-08-11 2012-09-28 Natura Cosmeticos Sa Compositions d'anti-transpirants et procedes permettant de reduire la transpiration chez les humains
US8653099B2 (en) 2008-08-19 2014-02-18 Janssen Pharmaceutica Cold menthol receptor antagonists
ES2377785B2 (es) * 2010-09-08 2012-09-26 Universidad Miguel Hernández De Elche Composición farmacéutica para el tratamiento del ojo seco.
KR102073258B1 (ko) 2014-04-15 2020-02-04 비쭈리 헬스 사이언스 엘엘씨 통증 완화용 국소 조성물, 제조방법 및 용도
ES2625393A1 (es) 2016-01-19 2017-07-19 Universidad Miguel Hernandez De Elche Compuestos agonistas del receptor trpm8 y sus aplicaciones
US20180252700A1 (en) 2016-10-06 2018-09-06 Ora, Inc. Screening agents in dry eye disease
US20220080048A1 (en) * 2016-10-12 2022-03-17 PS Therapy Ltd Opthalmological compositions and methods of use thereof
CN110996904A (zh) 2017-05-19 2020-04-10 奥古根有限公司 眼用组合物及使用方法
EP3705114A1 (en) 2019-03-06 2020-09-09 Avizorex Pharma, S.L. Ophthalmic composition for treating dry eye and symptoms thereof
WO2021195256A1 (en) 2020-03-24 2021-09-30 Aerie Pharmaceuticals, Inc. Pharmaceutical preparation
CA3242833A1 (en) 2021-12-17 2023-06-22 Alcon Inc. OPHTHALMIC PHARMACEUTICAL COMPOSITIONS AND THEIR USES

Also Published As

Publication number Publication date
JP2024544393A (ja) 2024-11-29
EP4447935A1 (en) 2024-10-23
IL313616A (en) 2024-08-01
AU2022409839B2 (en) 2025-12-11
US12336971B2 (en) 2025-06-24
MX2024007092A (es) 2024-06-26
CN118076340A (zh) 2024-05-24
US20230233493A1 (en) 2023-07-27
WO2023114986A1 (en) 2023-06-22
AU2026201834A1 (en) 2026-04-02
US20250281434A1 (en) 2025-09-11
US20240091179A1 (en) 2024-03-21
KR20240121320A (ko) 2024-08-08
AU2022409839A1 (en) 2024-07-11
US11850221B2 (en) 2023-12-26

Similar Documents

Publication Publication Date Title
EP3947353A4 (en) PHARMACEUTICAL COMPOSITIONS AND COMBINATIONS WITH ANDROGEN RECEPTOR INHIBITORS AND THEIR USES
EP4103539A4 (en) COMPOUNDS AND PHARMACEUTICAL USES THEREOF
EP4103210A4 (en) IMMUNOGENIC CORONAVIRUS COMPOSITIONS AND USES THEREOF
EP4232425A4 (en) Ctps1 inhibitors and uses thereof
MA54051A (fr) Dérivés de pyridinyl sulfonamide, compositions pharmaceutiques et leurs utilisations
EP3500255A4 (en) PHARMACEUTICAL COMPOSITIONS FOR EYE AND RELATED USE
EP4093768A4 (en) CAL-T CONSTRUCTS AND USES THEREOF
EP4388009A4 (en) Anti-ccr8 antibodies and uses thereof
EP3938369A4 (en) TYK2 INHIBITORS AND USES THEREOF
EP3914357A4 (en) TYK2 INHIBITORS AND USES THEREOF
EP4228614A4 (en) Improved dermatological compositions and uses thereof
EP4132974A4 (en) ANTI-CD98 ANTIBODIES AND USES THEREOF
EP4262750A4 (en) Protein formulations and uses thereof
EP3634415A4 (en) LOW DOSE COMBINATIONS OF BRIMONIDINE AND THEIR USES
EP4363425A4 (en) SMARCA DEGRADERS AND USES THEREOF
EP4281107A4 (en) ANTI-KIT ANTIBODIES AND USES THEREOF
EP4259612A4 (en) SMARCA DEGRADERS AND USES THEREOF
EP4017843A4 (en) Benzenesulfonamide derivatives and uses thereof
EP4010368A4 (en) Anti-nampt antibodies and uses thereof
EP3512522A4 (en) IN-SITU-MOMENTARY PHARMACEUTICAL COMPOSITIONS AND USES THEREOF FOR SINUS DISEASES
EP3966199A4 (en) NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF
EP3976009A4 (en) BAX INHIBITORS AND USES THEREOF
EP3849523A4 (en) DELAYED RELEASE OPHTHALMIC PHARMACEUTICAL COMPOSITIONS AND THEIR APPLICATIONS
EP3966201A4 (en) THIOSEMICARBAZATE AND THEIR USES
EP4121031A4 (en) 3-DIARYLMETHYLENE AND THEIR USE

Legal Events

Date Code Title Description
A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET

Effective date: 20240702

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT

Effective date: 20240702

P18 Priority claim added or amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P104 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR PRIORITY RECEIVED

Effective date: 20240702

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20240702

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W00-W00-W128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: INACTIVE: IPC ASSIGNED

Effective date: 20240702

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20240702

Free format text: ST27 STATUS EVENT CODE: A-1-1-W00-W00-W005 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: INACTIVE: FIRST IPC ASSIGNED

Effective date: 20240702

Free format text: ST27 STATUS EVENT CODE: A-1-1-W00-W00-W128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ARCHIVED EVENT: IPC ASSIGNED

Effective date: 20240702

Free format text: ST27 STATUS EVENT CODE: A-1-1-W00-W00-W005 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ARCHIVED EVENT: FIRST IPC ASSIGNED

Effective date: 20240702

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20240703

R11 Change to the name of applicant or owner or transfer of ownership requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R11-R127 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TRANSFER RECORDAL REQUEST OR RESPONSE

Effective date: 20240827

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241120

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241120

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241120

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250124

R14 Transfer of ownership recorded

Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R14-R129 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TRANSFER REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250315

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251118

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251118

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260728